Talecris Biotherapeutics - Comment

Document ID: FDA-2008-D-0379-0010
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: October 17 2008, at 04:16 PM Eastern Daylight Time
Date Posted: October 18 2008, at 12:00 AM Eastern Standard Time
Comment Start Date: July 30 2008, at 12:00 AM Eastern Standard Time
Comment Due Date: October 28 2008, at 11:59 PM Eastern Standard Time
Tracking Number: 807639bc
View Document:

This is comment on Notice

Draft Guidance for Industry: Nucleic Acid Testing to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products; Availability

View Comment

Please find attached comments on the Draft Guidance for Industry: Nucleic Acid Testing to Reduce the Possible Rish of Parvovirus B19 Transmission by Plasma- Derived Products (Docket No. FDA-2008-D-0379) provided by Talecris Biotherapeutics.

Attachments:

Talecris Biotherapeutics - Comment

Title:
Talecris Biotherapeutics - Comment

View Attachment:

Related Comments

Total: 4

CSL Behring - Comment
Public Submission Posted: 10/03/2008 ID: FDA-2008-D-0379-0009

Comment Period Closed
Oct 28,2008 11:59 PM ET

Talecris Biotherapeutics - Comment
Public Submission Posted: 10/18/2008 ID: FDA-2008-D-0379-0010

Comment Period Closed
Oct 28,2008 11:59 PM ET

PPTA - Comment
Public Submission Posted: 10/29/2008 ID: FDA-2008-D-0379-0011

Comment Period Closed
Oct 28,2008 11:59 PM ET

Cangene Corporation - Comment
Public Submission Posted: 10/29/2008 ID: FDA-2008-D-0379-0012

Comment Period Closed
Oct 28,2008 11:59 PM ET